XERS News and Press, Xeris Pharmaceuticals Inc. From 05/10/24

2024-05-10 10:00:12 ET David Amsellem from Piper Sandler issued a price target of $3.00 for XERS on 2024-05-10 08:29:00. The adjusted price target was set to $3.00. At the time of the announcement, XERS was trading at $1.8469. The overall price target consensus is at $6....

2024-05-09 12:49:14 ET Xeris Biopharma Holdings, Inc. (XERS) Q1 2024 Earnings Conference Call May 09, 2024, 08:30 ET Company Participants Allison Wey - SVP, IR & Corporate Communications Paul Edick - Chairman & CEO Steven Pieper - CFO Conference Cal...

2024-05-09 07:16:01 ET More on Xeris Pharmaceuticals Xeris Biopharma: Checking-In On One Of My 'Top Ideas' Xeris Biopharma (XERS) Q4 2023 Earnings Call Transcript Xeris Pharmaceuticals Q1 2024 Earnings Preview Xeris gains as Oppenheimer highlights drug techno...

Q1 2024 Total Revenue of $40.6M – up 22% over Q1 2023 Tightening full-year 2024 total revenue guidance to $175M-$200M Ended Q1 with $87.4M in cash, cash equivalents, and short-term investments, lowered borrowing rate of Hayfin debt by 2.05% Entered into a worldwide ...

2024-05-08 11:41:28 ET More on Xeris Pharmaceuticals Xeris Biopharma: Checking-In On One Of My 'Top Ideas' Xeris Biopharma (XERS) Q4 2023 Earnings Call Transcript Xeris gains as Oppenheimer highlights drug technology Xeris Pharmaceuticals Q4 2023 Earnings Pre...

For development and commercialization of a new and unique formulation of liquid stable glucagon for use in a bi-hormonal pump and pump systems Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing an...

Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the C...

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris’ Chairman and CEO, will pres...

2024-03-30 01:28:53 ET Summary Xeris Biopharma has not yet achieved cash flow breakeven and may no longer be a "Top Idea" in the Compounding Healthcare Investing Group. Xeris has three approved products and a strong pipeline, with potential for market penetration and revenue growt...

2024-03-28 13:11:15 ET More on Xeris Pharmaceuticals Xeris Biopharma (XERS) Q4 2023 Earnings Call Transcript Xeris Biopharma: Speculative Buy, Size Your Position Accordingly Xeris Biopharma Holdings Stock Is A Hold With Robust Performance Into 2024 Xeris Phar...